Event

Momentum's 2nd Due Diligence for Life Sciences Conference

Hosts

Fish’s Gwilym Attwell will speak at the 2nd Due Diligence for Life Sciences conference, on May 24th on the panels:

  • Evaluating the Intricacies and Value of Platform Deals for Due Diligence and the Business Development Process, and
  • Meet the Speakers Roundtables.

Fish is a proud supporter of Momentum and is passionate about Momentum’s commitment to developing events that attract the best and brightest minds. By collaborating with Momentum, we ensure that our events are engaging, content-driven, and provide value that you can apply to your career today and in the future. Behind every event is a proven research-based methodology that translates into the quality of information exchanged between industry stakeholders.

2nd Due Diligence for Life Sciences Conference
Monday, May 23 – Tuesday, May 24, 2022

This event will provide attendees with valuable insights and actionable strategies from cross-functional business development teams on how to execute optimal due diligence, licensing agreements, and M&A deals. This event serves as an educational platform for industry experts responsible for due diligence, R&D, search and evaluation, external innovation, legal/IP, portfolio management, alliance management, business development and licensing, and more. It will also highlight leadership representatives from biotechs, including mid-sized and large pharmaceutical, medical device, and diagnostics companies.

Evaluating the Intricacies and Value of Platform Deals for Due Diligence and the Business Development Process
Tuesday, May 24, 2022 | 12:30 p.m ET

Moderator: Ahmed Mousa, Pieris Pharmaceuticals

Speakers:

  • Christopher Mortko, Merck
  • Stefano Cottignoli, Chiesi Pharmaceuticals
  • Ravi Kiron, EMD Serono, Inc.
  • Gwilym Attwell, Fish & Richardson

Meet the Speakers Roundtables
Tuesday, May 24, 2022 | 1:45 p.m. ET

Speakers:

  • Ahmed Mousa, Pieris Pharmaceuticals
  • Christopher Mortko, Merck
  • Stefano Cottignoli, Chiesi Pharmaceuticals
  • Ravi Kiron, EMD Serono, Inc.
  • Gwilym Attwell, Fish & Richardson
  • Markus Decker, Simcere Pharmaceutical Group

To learn more, click here.